uniQure N.V.

Healthcare · Biotechnology · Netherlands

Last price 24.83 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.72B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ...